Imaging CRF X NOP Interactions in CUD

Status Recruiting

Clinical Trial Summary

This study uses [11C]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP interactions predict relapse in subjects with CUD.

Clinical Trial Description

Cocaine use disorder (CUD) is a chronic disorder associated with numerous relapses and periods of abstinence. Studies in CUD suggest that ~ 60 to 75% of abstinent addicts relapse over twelve months Documenting specific neurochemical abnormalities that lead to relapse in individuals with CUD has the potential to accelerate the development of medications to prevent relapse. Basic investigations postulate an imbalance between brain stress and anti-stress/resilience systems as the underlying mechanism that drives negative reinforcement, craving, and relapse in addiction. Nociceptin (N/OFQ), which binds to the nociceptive opioid peptide receptors (NOP) is a critical component of the brain's anti-stress system. N/OFQ counteracts the functional effects of the primary stress-promoting neuropeptide corticotrophin releasing factor (CRF) in the brain to exert its anti-stress effects. Studies have also shown that acute increases in CRF and stress are countered by increased NOP receptor expression (~ 10% ) in brain regions that regulate stress such as bed nucleus of the stria terminalis. PET studies with the NOP radiotracer [11C]NOP-1A show increased binding to NOP in CUD compared to HC. PET studies also show NOP receptors to upregulate (~ 15%) in response to an acute intravenous hydrocortisone challenge (1 mg/Kg). NOP upregulation may represent an adaptive mechanism in the brain to counteract stress-induced increases in cortisol and CRF. Here, we postulate a failure in this adaptive mechanism as a reason that leads to relapse in CUD. CUD subjects and HC will be studied with [11C]NOP-1A before and after an intravenous hydrocortisone challenge (aim 1). Hydrocortisone is used as a challenge because it increases cortisol and CRF in brain regions that regulate stress. We hypothesize that hydrocortisone-induced increases in [11C]NOP-1A binding (DELTA VT) will be smaller in CUD relative to HC, and this will be associated with less time to relapse in a 12-week follow up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05008146
Study type	Interventional
Source	University of Pittsburgh
Contact	Rajesh Narendran, MD
Phone	4126475176
Email	narendranr@upmc.edu
Status	Recruiting
Phase	Early Phase 1
Start date	December 31, 2020
Completion date	September 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03538548` - Treatment Outcome in CBT for Cocaine Use	N/A
Recruiting	`NCT04994821` - tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study	Phase 2
Not yet recruiting	`NCT06050304` - CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
Completed	`NCT02233647` - Phendimetrazine and Cocaine	Early Phase 1
Completed	`NCT02239913` - Topiramate-Phentermine Combinations for Cocaine Dependence	Phase 1
Recruiting	`NCT04927143` - Encouraging Abstinence Behavior in a Drug Epidemic	Phase 2
Completed	`NCT03224546` - Cocaine Use Reduction and Health	N/A
Recruiting	`NCT03656653` - Imagery-based Coping for Cocaine Use Disorder	N/A
Completed	`NCT03348384` - [11C]NOP-1A and Cocaine Use Disorders	Early Phase 1
Recruiting	`NCT05019430` - Cocaine and Zolmitriptan	Early Phase 1
Recruiting	`NCT03344419` - Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders	Phase 3
Recruiting	`NCT05507814` - Temporal Window and Episodic Future Thinking in CUD	N/A
Active, not recruiting	`NCT03799341` - Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project	N/A
Completed	`NCT02785406` - Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use	Phase 2
Completed	`NCT02798627` - Trial Of NS2359 For The Treatment of Cocaine Dependence	Phase 2
Completed	`NCT02444208` - A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use	N/A
Recruiting	`NCT05902819` - Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories	N/A
Recruiting	`NCT05521854` - Contingency Management for Drug Use: Does Age Matter?	N/A
Recruiting	`NCT05833529` - Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder	N/A
Completed	`NCT05557149` - Virtual Reality Exposure and Respiratory Relaxation-Based Coping With Cocaine Craving in Cocaine Users	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.